For immediate release |
1 September 2022 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Half Year Results,
Analyst Meeting and Webcast
Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the six months ended 30 June 2022 on Tuesday 20 September 2022.
A meeting for analysts will be held at 9.30am on the day of the results at Investec Bank plc, 30 Gresham Street, London EC2V 7QP. To register for the meeting, analysts should contact Buchanan [email protected].
A live webcast of the analyst meeting will be accessible via the following link:https://webcasting.buchanan.uk.com/broadcast/6307905bda906b287e99fad3
A recording of the webcast will be made available following the meeting at the investor section of Alliance's website,https://www.alliancepharmaceuticals.com/investors.
For further information:
Alliance Pharma plc |
+ 44 (0)1249 466966 |
Head of Investor Relations: Cora McCallum |
|
Buchanan |
+ 44 (0)20 7466 5000 |
Mark Court / Hannah Ratcliff |
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
Corporate Broking: James Black |
Investec Bank plc |
+ 44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams |
|
Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website:www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDNORSDLFMFEESELA
The service was requested through Alliance Pharma PLC. To modify your subscription, please subscribe again. If you no longer wish to receive these emails, you may unsubscribe at any time.
Supplied